Publications by authors named "Pei-Chen Ye"
Background: Metastatic castration-resistant prostate cancer (CRPC), the most refractory prostate cancer, inevitably progresses and becomes unresponsive to hormone therapy, revealing a pressing unmet need for this disease. Novel agents targeting HDAC6 and microtubule dynamics can be a potential anti-CRPC strategy.
Methods: Cell proliferation was examined in CRPC PC-3 and DU-145 cells using sulforhodamine B assay and anchorage-dependent colony formation assay.
Article Synopsis
- The study investigates the effectiveness of new small-molecule compounds targeting topoisomerase II and DNA repair mechanisms in treating castration-resistant prostate cancer (CRPC).
- A new series of azathioxanthone derivatives were developed, with several compounds (WC-A13, WC-A14, WC-A15) showing strong anti-CRPC properties, particularly by downregulating topoisomerase II proteins and causing mitochondrial dysfunction.
- The compounds also triggered specific DNA damage response pathways and exhibited varying effects on Rad51, an important protein involved in DNA repair, highlighting their potential as effective treatments for CRPC.